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Abstract: Obesity is a significant health problem that has been increasing steadily in the past 
several years. The investigation of obesity and its accompanying cardiometabolic complications 
is of critical importance. The endocannabinoid system serves to regulate both the central control 
of energy balance and peripheral metabolic processes. This regulation affects factors of risk 
associated with cardiometabolic processes. The endocannabinoid system (ECS) affects the 
transport of nutrients as well as metabolism and other physiologic processes. The ECS regulates 
these processes through endogenous ligands such as anandamide, 2-AG and CB1 receptors 
which are located in various places throughout the body. CB1 receptors can be found in the 
brain, digestive tract, muscle, and adipose tissue; the ECS has both central and peripheral 
components which are integrated through neuronal and hormonal signaling. Specifically, our 
focus will be on the peripheral components of the ECS to discover the plausibility of developing 
peripherally restricted DAGL inhibitors to play an important role in balancing energy levels. 
When the ECS is stimulated, one’s food intake and adiposity is increased. By extension, when 
CB1 receptors are not accessible, the food intake and adiposity is decreased. When specifically 
considering the stimulation of the ECS in the liver, it is apparent that lipogenesis occurs via the 
activation of hepatic lypogenic enzymes. There is also increased synthesis of fatty acids. The 
dysregulation of the metabolism can leader to many different harmful symptoms such as obesity, 
high blood pressure, resistance to insulin, etc. 
DAGL (diacylglycerol lipase) inhibitors have the potential to treat these aforementioned 
symptoms that result from the dysregulation of metabolism. In addition to this, it may also treat 
neuroinflammation, addictions, and pathological pain. The effectiveness of DAGL inhibitors 
needs to be investigated further and more in-depth to include more information about the 
possibility of developing subtype-selective (peripherally restricted) DAGL inhibitors. We 
propose that the discovery of peripherally restricted inhibitors’ ability to be developed will 
hold important headway in the treatment of certain metabolic disorders that are controlled 
by DAGLs. These compounds should not penetrate the central nervous system (CNS) due to the 
known adverse CNS side effects of CB1 antagonists.   
 The purpose of this research is to review the quantity and effectiveness of DAGL 
inhibitors to discover their potential to dissipate the affects, and possibly treat metabolic 
disorders and neurodegeneration. Increasing knowledge about this topic will help us to find out 
the plausibility of developing peripherally DAGL inhibitors. To do this, it is necessary to analyze 
the current assays that measure DAGL activity, of which there are several. The assay to be used 
employs activity-based protein profiling (ABPP). Of the six inhibitor classes identified, glycine 
sulfonides (reversible inhibitors of DAGL) have been found to be optimized to several 
compounds that have been found to be peripherally restricted, highly potent, and a dual 
DAGLα/βinhibitor. More information on compounds such as this can be invaluable in the 
progress and development of treatments for the metabolism disorders that are regulated by 
DAGL. 
